• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一种评估人类乳腺癌中雌激素受体结合数据的改进标准。

An improved criterion for the evaluation of estrogen receptor binding data in human breast cancer.

作者信息

di Fronzo G, Bertuzzi A, Ronchi E

出版信息

Tumori. 1978 Jun 30;64(3):259-66. doi: 10.1177/030089167806400303.

DOI:10.1177/030089167806400303
PMID:675855
Abstract

The evaluation of the data is an important step in performing the estrogen receptor test. For this reason an effort has been made to derive a more reliable threshold criteria. Among the parameters considered, Xo, Ka, and BI%, only the former 2 appear to be suitable to allow a proper evaluation of the results. From the analysis of different types of carcinomatous or normal breast specimens, limit values of these parameters have been recovered for positivity and negativity of the estrogen receptor test. We found all the samples showing Ka less than 1.5 x 10(9) M-1 or Xo less than 5 fmol/mg proteins to be negative, those characterized by low values of both the parameters were borderline, and all the remaining ones were positive.

摘要

数据评估是进行雌激素受体检测的重要步骤。因此,人们努力得出更可靠的阈值标准。在所考虑的参数Xo、Ka和BI%中,只有前两个参数似乎适合对结果进行恰当评估。通过对不同类型的癌性或正常乳腺标本进行分析,已得出这些参数用于雌激素受体检测阳性和阴性的极限值。我们发现,所有Ka小于1.5×10⁹ M⁻¹或Xo小于5 fmol/mg蛋白质的样本均为阴性,两个参数值均较低的样本为临界值,其余所有样本均为阳性。

相似文献

1
An improved criterion for the evaluation of estrogen receptor binding data in human breast cancer.一种评估人类乳腺癌中雌激素受体结合数据的改进标准。
Tumori. 1978 Jun 30;64(3):259-66. doi: 10.1177/030089167806400303.
2
Nuclear estradiol-binding sites in human breast cancer.
Cancer Res. 1983 Sep;43(9):4497-503.
3
Biological and clinical relevance of Kd values for estradiol binding in primary breast cancer tumors.原发性乳腺癌肿瘤中雌二醇结合解离常数(Kd值)的生物学及临床意义
Eur J Cancer Clin Oncol. 1988 Jul;24(7):1163-70. doi: 10.1016/0277-5379(88)90123-x.
4
Estrogen receptor cleavage and plasminogen activation by enzymes in human breast tumor cytosol.人乳腺肿瘤胞质溶胶中酶对雌激素受体的裂解及纤溶酶原激活作用
Endocrinology. 1980 Jun;106(6):1715-27. doi: 10.1210/endo-106-6-1715.
5
Correlation of lactogenic receptor concentration in human breast cancer with estrogen receptor concentration.人乳腺癌中催乳素受体浓度与雌激素受体浓度的相关性。
Cancer Res. 1984 May;44(5):1963-8.
6
Antiestrogen binding in antiestrogen growth-resistant estrogen-responsive clonal variants of MCF-7 human breast cancer cells.抗雌激素在MCF-7人乳腺癌细胞的抗雌激素生长抗性雌激素反应性克隆变体中的结合。
Cancer Res. 1984 Nov;44(11):5038-45.
7
Unoccupied binding sites for oestradiol in nuclei from human breast carcinomatous tissue.人乳腺癌组织细胞核中未被占据的雌二醇结合位点。
J Endocrinol. 1979 Mar;80(3):281-8. doi: 10.1677/joe.0.0800281.
8
Estradiol and progesterone receptor levels in human breast cancer in relation to cytosol and plasma estrogen level.人乳腺癌中雌二醇和孕酮受体水平与胞质溶胶及血浆雌激素水平的关系
J Steroid Biochem. 1983 Apr;18(4):459-63. doi: 10.1016/0022-4731(83)90066-3.
9
Glucose-6-phosphate dehydrogenase activity and estrogen receptors in human breast cancer.人类乳腺癌中的葡萄糖-6-磷酸脱氢酶活性与雌激素受体
J Steroid Biochem. 1983 Nov;19(5):1647-50. doi: 10.1016/0022-4731(83)90384-9.
10
Correlation between estrogen receptor protein and carcinoembryonic antigen in normal and carcinomatous human breast tissue.正常及癌性人乳腺组织中雌激素受体蛋白与癌胚抗原之间的相关性
Clin Chem. 1976 Aug;22(8):1366-71.

引用本文的文献

1
Relationship among estrogen receptors, proliferative activity and menopausal status in breast cancer.
Breast Cancer Res Treat. 1981;1(3):253-62. doi: 10.1007/BF01806265.
2
Bilateral ovariectomy in premenopausal patients with advanced breast cancer, after the evaluation of estrogen receptors and urinary androgen excretion.在评估雌激素受体和尿雄激素排泄后,对绝经前晚期乳腺癌患者进行双侧卵巢切除术。
Breast Cancer Res Treat. 1982;2(1):101-4. doi: 10.1007/BF01805722.
3
Estrogen-receptor status and response to chemotherapy in early and advanced breast cancer.
Cancer Chemother Pharmacol. 1980;4(1):37-41. doi: 10.1007/BF00255456.
4
Adjuvant chemotherapy in postmenopausal women: results of sequential noncross-resistant regimens.绝经后女性的辅助化疗:序贯非交叉耐药方案的结果
World J Surg. 1985 Oct;9(5):728-37. doi: 10.1007/BF01655188.